A share price of Carisma Therapeutics Inc [CARM] is currently trading at $0.45, down -17.62%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CARM shares have gain 132.90% over the last week, with a monthly amount glided 134.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Carisma Therapeutics Inc [NASDAQ: CARM] stock has seen the most recent analyst activity on December 12, 2024, when Robert W. Baird downgraded its rating to a Neutral and also revised its price target to $1 from $10. Previously, BTIG Research downgraded its rating to Neutral on December 10, 2024. On April 11, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $6 on the stock. CapitalOne started tracking the stock assigning a Overweight rating and suggested a price target of $10 on October 03, 2023. Evercore ISI initiated its recommendation with a Outperform and recommended $12 as its price target on July 06, 2023. Jefferies upgraded its rating to Buy for this stock on May 31, 2023, and upped its price target to $7. In a note dated May 24, 2023, H.C. Wainwright initiated an Buy rating and provided a target price of $10 on this stock.
Carisma Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.14 and $1.90. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Carisma Therapeutics Inc [NASDAQ: CARM] shares were valued at $0.45 at the most recent close of the market. An investor can expect a potential return of 1233.33% based on the average CARM price forecast.
Analyzing the CARM fundamentals
Trailing Twelve Months sales for Carisma Therapeutics Inc [NASDAQ:CARM] were 19.96M which represents 9.77% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.63%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.13%. To continue investigating profitability, this company’s Return on Assets is posted at -3.18, Equity is 2.7 and Total Capital is -7.75. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3638 points at the first support level, and at 0.2759 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6183, and for the 2nd resistance point, it is at 0.7849.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Carisma Therapeutics Inc [NASDAQ:CARM] is 1.34. As well, the Quick Ratio is 1.34, while the Cash Ratio is 0.74. Considering the valuation of this stock, the price to sales ratio is 0.95.
